The decision to administer adjuvant chemotherapy to a stage II colon cancer patient with poor prognostic factors should be made on a case-by-case basis, taking into consideration the potential benefits and risks of the treatment, as well as the MSI status of the cancer. The potential benefit of adjuvant chemotherapy in stage II cancers should be weighed against the toxicity of the treatment and the risk-benefit ratio.